Search Results

Suggested Topics within your search.
Refine Results
  1. 1
    Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study

    Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and... by Aguiar Júnior, Pedro, Barreto, Carmelia Maria Noia, Roitberg, Felipe, Lopes Júnior, Gilberto, del Giglio, Auro

    Published 2019
    Get full text
    Online
    Save to List
    Saved in:
  2. 2
    Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

    Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer by Wei Sun, Xun Yuan, Yijun Tian, Hua Wu, Hanxiao Xu, Guoqing Hu, Kongming Wu

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Icotinib in the Treatment of Non-Small-Cell Lung Cancer: A Systematic Review

    Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Icotinib in the Treatment of Non-Small-Cell Lung Cancer: A Systematic Review by Peter Ellis, N. Coakley, Ronald Feld, S. Kuruvilla, Yee Ung

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells

    Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells by Sivan Bokobza, Yanyan Jiang, Anika M. Weber, Aoife Devery, Anderson J. Ryan

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Cost‐effectiveness of epidermal growth factor receptor mutation testing and first‐line treatment with gefitinib for patients with advanced adenocarcinoma of the lung

    Cost‐effectiveness of epidermal growth factor receptor mutation testing and first‐line treatment with gefitinib for patients with advanced adenocarcinoma of the lung by Gilberto Lopes, Joel E. Segel, Daniel S.W. Tan, Kate Young, Tony Mok, Eric Finkelstein

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor

    Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor by Audrey Clapéron, Martine Mergey, Lynda Aoudjehane, Thanh Huong Nguyen Ho-Bouldoires, Dominique Wendum, Aurélie Prignon, Fatiha Merabtene, Delphine Firrincieli, Christèle Desbois‐Mouthon, Olivier Scatton, Filoména Conti, Chantal Housset, Laura Fouassier

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type

    MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type by Jiayu Li, Xuefei Li, Shengxiang Ren, Xiaoxia Chen, Yishi Zhang, Fei Zhou, Mingchuan Zhao, Chao Zhao, Xiu Chen, Ningning Cheng, Yinmin Zhao, Caicun Zhou, Fred R. Hirsch

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A

    Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A by Ting-Ting Chao, Cheng‐Yi Wang, Yen‐Lin Chen, Chih‐Cheng Lai, Fang-Yu Chang, Yi‐Ting Tsai, Chung-Hao H. Chao, Chung-Wai Shiau, Yuh-Chin T. Huang, Chong‐Jen Yu, Kuen‐Feng Chen

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma

    Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma by Chandraiah Godugu, Ravi Doddapaneni, Apurva R. Patel, Rakesh K. Singh, Roger S. Mercer, Mandip Singh

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones

    Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones by Antonio Marchetti, Michèle Milella, Lara Felicioni, Federico Cappuzzo, Luciana Irtelli, Maela Del Grammastro, Mariagrazia Sciarrotta, Sara Malatesta, Carmen Nuzzo, Giovanna Finocchiaro, Bruno Perrucci, Donatella Carlone, Alain Gelibter, Anna Ceribelli, Andrea Mezzetti, Stefano Iacobelli, Francesco Cognetti, Fiamma Buttitta

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Epidermal growth factor receptor‐targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis

    Epidermal growth factor receptor‐targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis by Bradley Curtis Carthon, Chaan S. Ng, Curtis A. Pettaway, Lance C. Pagliaro

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells

    Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells by Yongik Lee, Yian Wang, Michael A. James, Joseph H. Jeong, Ming You

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis

    Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis by Fang Nie, Jian Yang, Song Wen, Yanli An, Jie Ding, Shenghong Ju, Zhen Zhao, Hua‐Jun Chen, Xin‐Gui Peng, Stephen T.C. Wong, Hong Zhao, Gao‐Jun Teng

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

    Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib by Kimio Yonesaka, Kenji Hirotani, Hisato Kawakami, Masayuki Takeda, Hiroyasu Kaneda, Kazuko Sakai, Isamu Okamoto, Kazuto Nishio, Pasi A. Jänne, Kazuhiko Nakagawa

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

    Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells by Anne Camirand, Mahvash Zakikhani, Fiona B. Young, Michaël Pollak

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

    Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M by Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne, Geoffrey R. Oxnard

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition

    Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition by Hsin‐Yung Yen, Ying-Chih Liu, Nai-Yu Chen, Chia‐Feng Tsai, Yi‐Ting Wang, Yu‐Ju Chen, Tsui-Ling Hsu, Pan‐Chyr Yang, Chi‐Huey Wong

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition

    Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition by Irene Caffa, Vito D’Agostino, Patrizia Damonte, Debora Soncini, Michele Cea, Fiammetta Monacelli, Patrizio Odetti, Alberto Ballestrero, Alessandro Provenzani, Valter D. Longo, Alessio Nencioni

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT

    Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT by Jie Yang, Gang Qin, Moulun Luo, Jiangyuan Chen, Q Zhang, L Li, Ling Pan, Shanyu Qin

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Epidermal Growth Factor Receptor Mutations in Patients with Non–Small Cell Lung Cancer

    Epidermal Growth Factor Receptor Mutations in Patients with Non–Small Cell Lung Cancer by Bruce E. Johnson, Pasi A. Jänne

    Published 2005
    Get full text Get full text
    Revisão
    Save to List
    Saved in:

Search Tools: